title: [Mantle cell lymphoma: Towards a personalized therapeutic strategy?].
abstract: Mantle cell lymphoma (MCL) is a clinically heterogeneous non-Hodgkin lymphoma with an aggressive clinical behaviour and short survival in some cases and an indolent course in others. Advances in the biology and pathogenesis of MCL have unveiled several genes involved in deregulation of cell cycle checkpoints and the finding of subclonal populations with specific recurrent mutations (p53, ATM, NOTCH2) with an impact on disease progression and refractoriness to treatment. Prognostic stratification helps to distinguish between indolent and aggressive forms of MCL. Currently, younger fit patients benefit from more intensive front line chemotherapy regimens and consolidation with autologous transplantation, while older or frail patients are treated with less intensive regimens and rituximab maintenance. For relapsing disease, the introduction of bortezomib and lenalidomide containing regimens and B-cell receptor pathway inhibitors such as ibrutinib and idelalisib in combination with immunochemotherapy have emerged as therapeutic agents with promising clinical outcomes.
authors.affiliation: Servicio de Hematología y Hemoterapia, Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, Madrid, España.
authors.forename: Belén
authors.initials: B
authors.lastname: Navarro Matilla
authors.affiliation: Servicio de Hematología y Hemoterapia, Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, Madrid, España. Electronic address: jagarciam@aehh.org.
authors.forename: José A
authors.initials: JA
authors.lastname: García-Marco
mesh_terms: D000367:Age Factors; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003937:Diagnosis, Differential; D018450:Disease Progression; D018816:Genes, cdc; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage; D016130:Immunophenotyping; D007167:Immunotherapy; D020522:Lymphoma, Mantle-Cell / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics / Q000628:therapy*; D008232:Lymphoproliferative Disorders / Q000175:diagnosis; D058990:Molecular Targeted Therapy; D009154:Mutation; D009363:Neoplasm Proteins / Q000235:genetics; D010166:Palliative Care; D057285:Precision Medicine; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage; D016499:Radioimmunotherapy; D016879:Salvage Therapy
chemical_list: D007155:Immunologic Factors; D009363:Neoplasm Proteins; D047428:Protein Kinase Inhibitors
keywords: Diagnosis; Diagnóstico; Linfoma del manto; Mantle cell lymphoma; Tratamiento; Treatment